Latest current assets for AEZS: $33M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2024), AEZS shows a current assets of $33M. That compares with $46M in the prior-year period — down 27.6% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, AEZS's current assets is now $33M (was $46M) — a 27.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether COSCIENS Biopharma is outperforming or lagging.
Tracking AEZS's current assets over time shows whether COSCIENS Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $33M That compares with $46M in the prior-year period — down 27.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this current assets page, Stockcircle has COSCIENS Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current assets (currently $33M) with ownership activity and broader fundamentals.
COSCIENS Biopharma's current assets is $33M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.